NCT05510544 2023-03-13
Plerixafor for Poorly Mobilized Lymphoma
Peking University
Phase 4 Unknown
Peking University
University of Maryland, Baltimore
Nova Scotia Health Authority
Tufts Medical Center
Washington University School of Medicine
Sanofi
Sanofi
Sanofi
CancerCare Manitoba
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano